Advertisement

Helicobacter pylori cytotoxin-associated gene-A antibodies do not predict complications or death in type 2 diabetes: The Fremantle Diabetes Study

  • Author Footnotes
    1 Present address: Department of Endocrinology, Kantonsspital St. Gallen, Rorschacher Strasse 95, CH-9007 St. Gallen, Switzerland.
    Katrin Schimke
    Footnotes
    1 Present address: Department of Endocrinology, Kantonsspital St. Gallen, Rorschacher Strasse 95, CH-9007 St. Gallen, Switzerland.
    Affiliations
    School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia
    Search for articles by this author
  • Stephen A.P. Chubb
    Affiliations
    Biochemistry Department, PathWest, Fremantle Hospital, Fremantle, Australia
    Search for articles by this author
  • Wendy A. Davis
    Affiliations
    School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia
    Search for articles by this author
  • Timothy M.E. Davis
    Correspondence
    Corresponding author at: University of Western Australia, School of Medicine and Pharmacology, Fremantle Hospital, PO Box 480, Fremantle, WA 6959, Australia. Tel.: +61 8 9431 3229; fax: +61 8 9431 2977.
    Affiliations
    School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia
    Search for articles by this author
  • Author Footnotes
    1 Present address: Department of Endocrinology, Kantonsspital St. Gallen, Rorschacher Strasse 95, CH-9007 St. Gallen, Switzerland.

      Abstract

      Objectives

      There is cross-sectional evidence that CagA antigen produced by Helicobacter pylori is associated with coronary heart disease, stroke, atrial fibrillation (AF) and microalbuminuria, but no large-scale longitudinal studies have been conducted in diabetic patients. We aimed to determine whether cytotoxin-associated gene-A (CagA) seropositivity is independently associated with important vascular outcomes in type 2 diabetes.

      Methods

      We studied 1179 type 2 patients from a well characterized community-based cohort who had available sera from baseline assessment between 1993 and 1996, and follow-up for incident events to end-June 2007. H. pylori IgG and CagA antibodies at baseline were measured by validated ELISA. Multiple logistic/linear regression analysis and Cox proportional hazards modelling were used to determine independent baseline associates of prevalent and incident complications, respectively, including H. pylori/CagA serostatus.

      Results

      At baseline, 62.0% of patients were H. pylori seropositive and 37.7% were both H. pylori and CagA seropositive. CagA seropositivity was not independently associated with prevalent coronary heart disease (CHD), cerebrovascular disease (CVD), peripheral arterial disease or AF at baseline (P > 0.41), but there was a significant inverse association with ln(urinary albumin:creatinine) (P = 0.033). There were no independent associations between CagA seropositivity and incident CHD/CVD or progression to microalbuminuria (P > 0.20). During follow-up, 480 patients (40.7%) died, 246 (50.2%) from cardiovascular causes. After adjustment for other variables, CagA seropositivity was weakly protective against cardiovascular death (P = 0.024).

      Conclusion

      CagA seropositivity is not a risk factor for chronic vascular complications of type 2 diabetes. Assay of CagA antibodies does not contribute significantly to clinical management outside gastroenterological indications.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Crabtree J.E.
        • Kersulyte D.
        • Li S.D.
        • Lindley I.J.
        • Berg D.E.
        Modulation of Helicobacter pylori induced interleukin-8 synthesis in gastric epithelial cells mediated by cag PAI encoded VirD4 homologue.
        J Clin Pathol. 1999; 52: 653-657
        • Ameriso S.F.
        • Fridman E.A.
        • Leiguarda R.C.
        Detection of Helicobacterpylori in human carotid arteries.
        Stroke. 2001; 32: 385-391
        • Lindsberg P.J.
        • Grau A.J.
        Inflammation and infections as risk factors for ischemic stroke.
        Stroke. 2003; 34: 2518-2532
        • Zhang S.
        • Guo Y.
        • Ma Y.
        • Teng Y.
        Cytotoxin-associated gene-A-seropositive virulent strains of Helicobacter pylori and atherosclerotic diseases: a systematic review.
        Chin Med J (Engl). 2008; 121: 946-951
        • Bunch T.J.
        • Day J.D.
        • AndersonJL
        • et al.
        Frequency of Helicobacter pylori seropositivity and C-reactive protein increase in atrial fibrillation in patients undergoing coronary angiography.
        Am J Cardiol. 2008; 101: 848-851
        • Lunetta M.
        • Fazio G.
        • Avena V.
        • et al.
        Helicobacter pylori and atrial fibrillation: absence of correlations.
        J Cardiovasc Med (Hagerstown). 2009; 10: 4-5
        • Badran H.M.
        • Mahfouz M.E.
        Cytotoxin-associated gene-A bearing strains of Helicobacter pylori and atrial fibrillation due to ischemic origin: is there a link?.
        Eur J Cardiovasc Prev Rehabil. 2007; 14: 518-520
        • Dore M.P.
        • Bilotta M.
        • Malaty H.M.
        • et al.
        Diabetes mellitus and Helicobacter pylori infection.
        Nutrition. 2000; 16: 407-410
        • Ongey M.
        • Brenner H.
        • Thefeld W.
        • Rothenbacher D.
        Helicobacter pylori and hepatitis A virus infections and the cardiovascular risk profile in patients with diabetes mellitus: results of a population-based study.
        Eur J Cardiovasc Prev Rehabil. 2004; 11: 471-476
        • Schimke K.
        • Chubb S.A.
        • Davis W.A.
        • Phillips P.
        • Davis T.M.
        Antiplatelet therapy, Helicobacter pylori infection and complicated peptic ulcer disease in diabetes: the Fremantle Diabetes Study.
        Diabet Med. 2009; 26: 70-75
        • Pietroiusti A.
        • Giuliano M.
        • Magrini A.
        • Bergamaschi A.
        • Galante A.
        Cytotoxin-associated gene A strains of Helicobacter pylori represent a risk factor for the development of microalbuminuria in type 2 diabetes.
        Diabetes Care. 2006; 29: 1399-1401
        • Franceschi F.
        • Sepulveda A.R.
        • Gasbarrini A.
        • et al.
        Cross-reactivity of anti-CagA antibodies with vascular wall antigens: possible pathogenic link between Heli-cobacter pylori infection and atherosclerosis.
        Circulation. 2002; 106: 430-434
        • Yudkin J.S.
        • Forrest R.D.
        • Jackson C.A.
        Microalbuminuria as predictor of vascular disease in non-diabetic subjects, Islington Diabetes Survey.
        Lancet. 1988; 2: 530-533
        • Stehouwer C.D.
        • Nauta J.J.
        • Zeldenrust G.C.
        • et al.
        Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus.
        Lancet. 1992; 340: 319-323
        • Davis T.M.
        • Zimmet P.
        • Davis W.A.
        • et al.
        Autoantibodies to glutamic acid decarboxylase in diabetic patients from a multi-ethnic Australian community: the Fremantle Diabetes Study.
        Diabet Med. 2000; 17: 667-674
        • Davis W.A.
        • Norman P.E.
        • Bruce D.G.
        • Davis T.M.
        Predictors, consequences and costs of diabetes-related lower extremity amputation complicating type 2 diabetes: the Fremantle Diabetes Study.
        Diabetologia. 2006; 49: 2634-2641
        • Levey A.S.
        • Bosch J.P.
        • Lewis J.B.
        • et al.
        A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in Renal Disease Study Group.
        Ann Inter Med. 1999; 130: 461-470
        • Feldman E.L.
        • Stevens M.J.
        • Thomas P.K.
        • et al.
        A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy.
        Diabetes Care. 1994; 17: 1281-1289
        • Laheij R.J.
        • Straatman H.
        • Jansen J.B.
        Verbeek AL Evaluation of commercially available Helicobacter pylori serology kits: a review.
        J Clin Microbiol. 1998; 36: 2803-2809
        • Basso D.
        • Stefani A.
        • Brigato L.
        • et al.
        Serum antibodies anti-H. pylori and anti-CagA: a comparison between four different assays.
        J Clin Lab Anal. 1999; 13: 194-198
        • Holman C.D.
        • Bass A.J.
        • Rouse I.L.
        • Hobbs M.S.
        Population-based linkage of health records in Western Australia: development of a health services research linked database.
        Aust N Z J Public Health. 1999; 23: 453-459
      1. UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998:352:837-53.

        • Anastasios R.
        • Goritsas C.
        • Papamihail C.
        • et al.
        Helicobacter pylori infection in diabetic patients: prevalence and endoscopic findings.
        Eur J Intern Med. 2002; 13: 376-379
        • Sugimoto M.
        • Yamaoka Y.
        Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy.
        Arch Immunol Ther Exp (Warsz). 2009; 57: 45-56
        • Markus H.S.
        • Risley P.
        • Mendall M.A.
        • Steinmetz H.
        • Sitzer M.
        Helicobacter pylori infection, the cytotoxin gene A strain, and carotid artery intima-media thickness.
        J Cardiovasc Risk. 2002; 9: 1-6
        • Andrew P.
        • Montenero A.S.
        Is Helicobacter pylori a cause of atrial fibrillation?.
        Future Cardiol. 2006; 2: 429-439
        • Platonov P.
        • Ekesbo R.
        • Hansson A.
        • et al.
        Permanent atrial fibrillation in patients without structural heart disease is not associated with signs of infection by Chlamydia pneumoniae and Helicobacter pylori.
        Acta Cardiol. 2008; 63: 479-484
      2. Kowalski M. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque. J Physiol Pharmacol 2001:52:3-31.

        • Stone A.F.
        • Mendall M.A.
        • Kaski J.C.
        • et al.
        Effect of treatment for Chlamydia pneu-moniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA).
        Circulation. 2002; 106: 1219-1223
        • Yusuf S.
        • Hawken S.
        • Ounpuu S.
        • et al.
        Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.
        Lancet. 2004; 364: 937-952